Last reviewed · How we verify
BCG Tokyo-172 Strain Vaccine
BCG Tokyo-172 Strain Vaccine is a Live attenuated vaccine Biologic drug developed by SWOG Cancer Research Network. It is currently in Phase 3 development for Bladder cancer (non-muscle invasive), Metastatic melanoma (in combination with other immunotherapies). Also known as: Bacillus Calmette-Guerin Tokyo-172 Strain Vaccine.
BCG Tokyo-172 is a live attenuated Mycobacterium bovis vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.
BCG Tokyo-172 is a live attenuated Mycobacterium bovis vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity. Used for Bladder cancer (non-muscle invasive), Metastatic melanoma (in combination with other immunotherapies).
At a glance
| Generic name | BCG Tokyo-172 Strain Vaccine |
|---|---|
| Also known as | Bacillus Calmette-Guerin Tokyo-172 Strain Vaccine |
| Sponsor | SWOG Cancer Research Network |
| Drug class | Live attenuated vaccine |
| Target | Pattern recognition receptors (TLR2, TLR4, NOD2) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BCG Tokyo-172 works as an immunotherapeutic agent by activating dendritic cells and T cells through pattern recognition receptors, promoting a Th1-type immune response. This strain has been studied in combination with other immunotherapies to enhance anti-tumor activity, particularly in bladder cancer and other malignancies. The vaccine aims to prime the immune system to recognize and eliminate cancer cells.
Approved indications
- Bladder cancer (non-muscle invasive)
- Metastatic melanoma (in combination with other immunotherapies)
Common side effects
- Local injection site reactions
- Fever
- Fatigue
- BCG-itis (systemic BCG infection)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG Tokyo-172 Strain Vaccine CI brief — competitive landscape report
- BCG Tokyo-172 Strain Vaccine updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI
Frequently asked questions about BCG Tokyo-172 Strain Vaccine
What is BCG Tokyo-172 Strain Vaccine?
How does BCG Tokyo-172 Strain Vaccine work?
What is BCG Tokyo-172 Strain Vaccine used for?
Who makes BCG Tokyo-172 Strain Vaccine?
Is BCG Tokyo-172 Strain Vaccine also known as anything else?
What drug class is BCG Tokyo-172 Strain Vaccine in?
What development phase is BCG Tokyo-172 Strain Vaccine in?
What are the side effects of BCG Tokyo-172 Strain Vaccine?
What does BCG Tokyo-172 Strain Vaccine target?
Related
- Drug class: All Live attenuated vaccine drugs
- Target: All drugs targeting Pattern recognition receptors (TLR2, TLR4, NOD2)
- Manufacturer: SWOG Cancer Research Network — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Bladder cancer (non-muscle invasive)
- Indication: Drugs for Metastatic melanoma (in combination with other immunotherapies)
- Also known as: Bacillus Calmette-Guerin Tokyo-172 Strain Vaccine
- Compare: BCG Tokyo-172 Strain Vaccine vs similar drugs
- Pricing: BCG Tokyo-172 Strain Vaccine cost, discount & access